Williams, Michael

Nomenclature and classification of purinoceptors.

Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., & Williams, M. (1994) · Pharmacological Reviews

Adenosine and Purinergic SignalingReceptor Mechanisms and Signaling

Cited by 1,585

Neuronal nicotinic receptors: A perspective on two decades of drug discovery research

Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology

Nicotinic Acetylcholine Receptors StudySmoking Behavior and Cessation

Cited by 208

Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps

Jarvis, M. F., & Williams, M. (2016) · Trends in Pharmacological Sciences

Animal testing and alternativesAcademic Publishing and Open Access

Cited by 129

Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality

Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 98

Structure−Activity Studies on 2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-Enhancing Properties

Lin, N.-H., Gunn, D. E., Ryther, K. B., Garvey, D. S., Donnelly-Roberts, D. L., Decker, M. W., Brioni, J. D., Buckley, M. J., Rodrigues, A. D., Marsh, K. G., et al. (1997) · Journal of Medicinal Chemistry

Nicotinic Acetylcholine Receptors StudyCholinesterase and Neurodegenerative Diseases

Cited by 67

Behavioral responses of dopamine β-hydroxylase knockout mice to modafinil suggest a dual noradrenergic–dopaminergic mechanism of action

Mitchell, H. A., Bogenpohl, J. W., Liles, L. C., Epstein, M. P., Bozyczko-Coyne, D., Williams, M., & Weinshenker, D. (2008) · Pharmacology Biochemistry and Behavior

Neurotransmitter Receptor Influence on BehaviorSleep and Wakefulness Research

Cited by 51

Alzheimer’s Disease (AD) Therapeutics—2: Beyond Amyloid—Re-Defining AD and Its Causality to Discover Effective Therapeutics

Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 32

Enhancing reproducibility: Failures from Reproducibility Initiatives underline core challenges

Mullane, K., & Williams, M. (2017) · Biochemical Pharmacology

Academic Publishing and Open AccessScientific Computing and Data Management

Cited by 28